/PRNewswire/ AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers,.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such.
Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) Director David R. Epstein purchased 30,000 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $1.44 per share, with a total value of $43,200.00. Following the acquisition, the director now directly owns 4,720,012 shares of […]